1361208-77-6

Upstream product

• 73870-24-3 4-bromomethyl pyridine hydrobromide 
• 40615-39-2 5'-O-(4-4'-dimethoxytrityl)thymidine 
• 54751-01-8 4-(bromomethyl)pyridine 

Downstream Products

• 1367360-07-3 3-(4-pyridylmethyl)-3'-O-cholesteroxyacetyl-5-O-(4,4'-dimethoxytriphenylmethyl)thymidine 
• 1361208-80-1 3-(4-pyridylmethyl)-3’-O-oleyl-5’-O-(4,4′-dimethoxytriphenylmethyl)-thymidine 
• 1361209-04-2 3-(4-pyridylmethyl)-3’-O-oleyl-5’-O-(benzyloxy)hexaethylene glycol acetylthymidine 

Relevant academic research and scientific papers

AS1411-decorated niosomes as effective nanocarriers for Ru(III)-based drugs in anticancer strategies

Niosomes are self-assembled vesicles made up of single chain non-ionic surfactants combined with appropriate amounts of cholesterol or other lipids, exploited as carriers for hydrophilic or lipophilic drugs. Compared to liposomes, niosomes are typically more stable, less expensive and, being generally obtained from synthetic surfactants, more easily derivatizable, providing vesicular structures with a higher versatility and chemical diversity. Herein, we investigated the physico-chemical and biological properties of niosomes loaded with two active ingredients, i.e. the nucleolipidic Ru(iii)-complex HoThyRu, selected as an anticancer agent, and the nucleolin-targeting AS1411 aptamer, allowing selective recognition of cancer cells. The morphology, average size, zeta potential, electrophoretic mobility, and stability over time of the functionalized niosomes were analyzed using different biophysical techniques. These formulations, tested on both cancer and normal cells, showed promising antiproliferative activity on HeLa cells, with a higher efficacy associated with the nanosystems containing both AS1411 and HoThyRu with respect to the controls. In all the tested cell lines, AS1411 proved to markedly enhance the bioactivity of the Ru(iii)-containing niosomes.

Cholesterol-based nucleolipid-ruthenium complex stabilized by lipid aggregates for antineoplastic therapy

A novel ruthenium complex, linked to a cholesterol-containing nucleolipid (named ToThyCholRu), stabilized by lipid aggregates for antineoplastic therapy is presented. In order to retard the degradation kinetics typically observed for several ruthenium-based antineoplastic agents, ToThyCholRu is incorporated into a liposome bilayer formed by POPC. The resulting nanoaggregates contain up to 15% in moles of the ruthenium complex, and are shown to be stable for several weeks. The liposomes host the ruthenium - nucleolipid complex with the metal ion surrounded by POPC lipid headgroups and the steroid moiety inserted in the more external acyl chain region. These rutheniumcontaining liposomes are more effective in inhibiting the growth of cancer cells than a model NAMI-A-like ruthenium complex, prepared for a direct evaluation of their antiproliferative activity. These results introduce new perspectives in the design of innovative transition-metal-based supramolecular systems for anticancer drug vectorization. (Graph Presented)

Nucleolipid nanovectors as molecular carriers for potential applications in drug delivery

Novel thymidine- or uridine-based nucleolipids, containing one hydrophilic oligo(ethylene glycol) chain and one or two oleic acid residues (called ToThy, HoThy and DoHu), have been synthesized with the aim to develop bio-compatible nanocarriers for drug d